BENBROOK, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the fourth fiscal quarter and full year 2025. Highlights from 2025: Revenues were $76.3 million, up 2.6% from 2024Generated operating loss of $1.0 million versus income of $0.6 million in 2024Net income of $9.1 million versus $0.8 million in 2024Gross margins of 57.0%, up from 56.2% in 2024Operating expenses $44.5 million, up 8.1% from 2024Adjusted EBITDA* (from op ...

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 millionFully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow exiting 202 ...

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Comp ...

Stock Repurchase Program - Valley National Bancorp's Board of Directors approved a new stock repurchase program for up to 25 million shares of common stock, effective from April 27, 2026, to April 27, 2028 [1][2] - The current stock repurchase program is set to expire on April 26, 2026, unless terminated sooner [1] Repurchase Methods and Flexibility - Repurchases can be conducted through various methods, including open market purchases and Rule 10b5-1 trading plans, in compliance with SEC regulations [2] - The program does not obligate Valley to acquire a specific number of shares and can be suspended or discontinued at the company's discretion [2] Company Overview - Valley National Bank, a regional financial institution and principal subsidiary of Valley National Bancorp, has approximately $64 billion in assets and operates over 200 offices across several states [3] - The bank offers a full range of consumer, commercial, and wealth management solutions, emphasizing a relationship-led approach to support community investment and corporate citizenship [3]

Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant currency revenue* an ...

Core Insights - Vaxcyte is advancing its VAX-31 adult Phase 3 clinical program, with three studies underway to support a planned Biologics License Application (BLA) submission, aiming to establish a new standard for adult pneumococcal vaccines [3][4] - The company has completed enrollment in the VAX-31 infant Phase 2 dose-finding study, with results expected by the end of the first half of 2027 [1][7] - Vaxcyte has approximately $2.4 billion in cash and investments as of December 31, 2025, bolstered by a recent equity offering [3][12] Clinical Development - The VAX-31 adult Phase 3 program includes OPUS-1, OPUS-2, and OPUS-3 trials, with around 6,000 adults expected to be enrolled, and approximately 3,400 participants receiving the vaccine [4][5] - OPUS-1 is a pivotal noninferiority trial evaluating VAX-31 against current standard-of-care vaccines, with the first participants dosed in December 2025 [5] - OPUS-2 and OPUS-3 trials have also commenced, focusing on different adult populations and evaluating the vaccine's safety and immunogenicity [5][6] Infant Vaccine Development - The VAX-31 infant Phase 2 study aims to evaluate safety and immunogenicity compared to PCV20, with a three-dose primary immunization series followed by a booster [7][9] - Positive interim data from the VAX-24 infant Phase 2 study has informed the ongoing VAX-31 infant study, leading to the inclusion of optimized dosing [9][10] Early-Stage Pipeline - Vaxcyte plans to initiate a Phase 1 adult clinical study for VAX-A1, a vaccine candidate targeting Group A Strep, in 2026 [8][17] Manufacturing and Supply Chain - The company has made significant progress in manufacturing capabilities, including the completion of a dedicated facility with Lonza and the initiation of a fill-finish line in North Carolina [11][12] Financial Performance - For the year ended December 31, 2025, Vaxcyte reported a net loss of $766.6 million, an increase from $463.9 million in 2024, primarily due to higher R&D expenses [22][27] - R&D expenses for Q4 2025 were $242.1 million, compared to $133.6 million in Q4 2024, reflecting increased development activities [22][26] Leadership and Governance - Vaxcyte has strengthened its leadership team with the addition of experienced industry executives to support its late-stage programs and commercialization efforts [13][16]

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET. To listen to a live webcast of this event, or access an archived we ...

Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ...

FY2025 Net Sales $1.49 Billion and Diluted EPS of $5.24 Per Share; Reaffirms FY2026 Guidance and Maintains Annual Cash Dividend of $3.20 for 2026 NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today reported record results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:($ in millions, except per share amounts)Three Months EndedDecember 31,Year EndedDecember 31,20252024% Change20252024% Ch ...

THORNTON, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United States and Canada, announced it will attend the Jefferies Power, Energy, Clean Energy & Utilities investor conference. MYR Group’s Chief Executive Officer, Rick Swartz; Chief Financial Officer, Kelly Huntington; and Vice President, Investor Relations and Trea ...